Ocrelizumab extended interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.

Simone GuerrieriChiara BuccaAgostino NozzolilloAngela GenchiChiara ZanettaIlaria CettaGiulia RugarliIrene GattusoMatteo AzzimontiMaria Assunta RoccaLucia MoiolaMassimo Filippinull null

Published in: European journal of neurology (2023)

sporadic ocrelizumab administration delay granted sustained treatment efficacy in our cohort. Prospective data should be obtained to confirm these observations and set-up systematic extended-interval regimens.

Keyphrases

sars cov
multiple sclerosis
respiratory syndrome coronavirus
coronavirus disease
big data
amyotrophic lateral sclerosis
combination therapy